Lytic peptide-mediated sensitization of TRAIL-resistant prostate cancer cells to death receptor agonists

Cancer Letters

Volumn 293, Issue 2, 2010, Pages 240-253

  Barua, Sutapa ^a   Linton, Rebecca S ^a   Gamboa, Jennifer ^a   Banerjee, Ipsita ^b   Yarmush, Martin L ^b,d   Rege, Kaushal ^a,c  

^a Arizona State University   (United States)

^b SHRINERS HOSPITALS FOR CHILDREN   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

^d RUTGERS UNIVERSITY   (United States)

Author keywords

Combination treatments; Death receptors; Lytic peptides; Prostate cancer; TRAIL

Indexed keywords

ALANINE; AMINO ACID; CASPASE 3; CYSTEINE; CYTOCHROME C; CYTOKINE RECEPTOR AGONIST; DEATH RECEPTOR 4; DEATH RECEPTOR 5; HISTIDINE; LEUCINE; LYSINE; PROTEIN KLA; SYNTHETIC PEPTIDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DEATH RECEPTOR; KLA PEPTIDE; PEPTIDE;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL LOSS; CELL STRAIN LNCAP; CELL VIABILITY; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIZATION; ENZYME DEGRADATION; HUMAN; HUMAN CELL; LIPID RAFT; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; DRUG RESISTANCE; MALE; METABOLISM; PROSTATE TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PEPTIDES; PROSTATIC NEOPLASMS; RECEPTORS, DEATH DOMAIN; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77952474125     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.01.012     Document Type: Article

References (53)

1. Nelson W.G., De Marzo A.M., Isaacs W.B. Prostate cancer. New Engl. J. Med. 2003, 349:366-381.
2. Zietman A.L., Shipley W.U., Willett C.G. Residual disease after radical surgery or radiation therapy for prostate cancer. Clinical significance and therapeutic implications. Cancer 1993, 71:959-969.
3. Zhang L., Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 2005, 12:228-237.
4. Almasan A., Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 2003, 14:337-348.
5. Baetu T.M., Hiscott J. On the TRAIL to apoptosis. Cytokine Growth Factor Rev. 2002, 13:199-207.
6. Bouralexis S., Findlay D.M., Evdokiou A. Death to the bad guys: targeting cancer via Apo2L/TRAIL. Apoptosis 2005, 10:35-51.
7. Fiorucci G., Vannucchi S., Chiantore M.V., Percario Z.A., Affabris E., Romeo G. TNF-related apoptosis-inducing ligand (TRAIL) as a pro-apoptotic signal transducer with cancer therapeutic potential. Curr. Pharm. Des. 2005, 11:933-944.
8. Kelley S.K., Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr. Opin. Pharmacol. 2004, 4:333-339.
9. Thorburn A. Death receptor-induced cell killing. Cell Signal 2004, 16:139-144.
10. Hopkins-Donaldson S., Bodmer J.L., Bourloud K.B., Brognara C.B., Tschopp J., Gross N. Loss of caspase-8 expression in neuroblastoma is related to malignancy and resistance to TRAIL-induced apoptosis. Med. Pediatr. Oncol. 2000, 35:608-611.
11. Hopkins-Donaldson S., Bodmer J.L., Bourloud K.B., Brognara C.B., Tschopp J., Gross N. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 2000, 60:4315-4319.
12. Grotzer M.A., Eggert A., Zuzak T.J., Janss A.J., Marwaha S., Wiewrodt B.R., Ikegaki N., Brodeur G.M., Phillips P.C. Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene 2000, 19:4604-4610.
13. Chen X., Thakkar H., Tyan F., Gim S., Robinson H., Lee C., Pandey S.K., Nwokorie C., Onwudiwe N., Srivastava R.K. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 2001, 20:6073-6083.
14. Zhang X.D., Franco A., Myers K., Gray C., Nguyen T., Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res. 1999, 59:2747-2753.
15. Zhang S., Shen H.M., Ong C.N. Down-regulation of c-FLIP contributes to the sensitization effect of 3,3′-diindolylmethane on TRAIL-induced apoptosis in cancer cells. Mol. Cancer Ther. 2005, 4:1972-1981.
16. Fulda S., Meyer E., Debatin K.M. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 2002, 21:2283-2294.
17. Kim M.R., Lee J.Y., Park M.T., Chun Y.J., Jang Y.J., Kang C.M., Kim H.S., Cho C.K., Lee Y.S., Jeong H.Y., Lee S.J. Ionizing radiation can overcome resistance to TRAIL in TRAIL-resistant cancer cells. FEBS Lett. 2001, 505:179-184.
18. Shankar S., Singh T.R., Srivastava R.K. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: intracellular mechanisms. Prostate 2004, 61:35-49.
19. Ohtsuka T., Buchsbaum D., Oliver P., Makhija S., Kimberly R., Zhou T. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 2003, 22:2034-2044.
20. Zisman A., Ng C.P., Pantuck A.J., Bonavida B., Belldegrun A.S. Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis. J. Immunother. 2001, 24:459-471.
21. Sun S.Y., Yue P., Lotan R. Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells. Oncogene 2000, 19:4513-4522.
22. Woods D.C., Liu H.K., Nishi Y., Yanase T., Johnson A.L. Inhibition of proteasome activity sensitizes human granulosa tumor cells to TRAIL-induced cell death. Cancer Lett. 2008, 260:20-27.
23. Fulda S., Debatin K.M. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res. 2004, 64:337-346.
24. Shai Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim. Biophys. Acta 1999, 1462:55-70.
25. De Smet K., Contreras R. Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol. Lett. 2005, 27:1337-1347.
26. Javadpour M.M., Juban M.M., Lo W.C., Bishop S.M., Alberty J.B., Cowell S.M., Becker C.L., McLaughlin M.L. De novo antimicrobial peptides with low mammalian cell toxicity. J. Med. Chem. 1996, 39:3107-3113.
27. Ellerby H.M., Arap W., Ellerby L.M., Kain R., Andrusiak R., Rio G.D., Krajewski S., Lombardo C.R., Rao R., Ruoslahti E., Bredesen D.E., Pasqualini R. Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med. 1999, 5:1032-1038.
28. Mai J.C., Mi Z., Kim S.H., Ng B., Robbins P.D. A proapoptotic peptide for the treatment of solid tumors. Cancer Res. 2001, 61:7709-7712.
29. Marks A.J., Cooper M.S., Anderson R.J., Orchard K.H., Hale G., North J.M., Ganeshaguru K., Steele A.J., Mehta A.B., Lowdell M.W., Wickremasinghe R.G. Selective apoptotic killing of malignant hemopoietic cells by antibody-targeted delivery of an amphipathic peptide. Cancer Res. 2005, 65:2373-2377.
30. Rege K., Patel S.J., Megeed Z., Yarmush M.L. Amphipathic peptide-based fusion peptides and immunoconjugates for the targeted ablation of prostate cancer cells. Cancer Res. 2007, 67:6368-6375.
31. Kolonin M.G., Saha P.K., Chan L., Pasqualini R., Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nat. Med. 2004, 10:625-632.
32. Gong M.C., Latouche J.B., Krause A., Heston W.D., Bander N.H., Sadelain M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1999, 1:123-127.
33. Smiley S.T., Reers M., Mottola-Hartshorn C., Lin M., Chen A., Smith T.W., Steele G.D., Chen L.B. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc. Natl. Acad. Sci. USA 1991, 88:3671-3675.
34. Rasband W.S. ImageJ 2004, National Institutes of Health, Bethesda, Maryland, USA.
35. Nagane M., Pan G., Weddle J.J., Dixit V.M., Cavenee W.K., Huang H.J. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res. 2000, 60:847-853.
36. Song J.H., Bellail A., Tse M.C., Yong V.W., Hao C. Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. J. Neurosci. 2006, 26:3299-3308.
37. Voelkel-Johnson C. An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells. Cancer Biol. Ther. 2003, 2:283-290.
38. Berenbaum M.C. Synergy, additivism and antagonism in immunosuppression. A critical review. Clin. Exp. Immunol. 1977, 28:1-18.
39. Cho W.J., Daniel E.E. Colocalization between caveolin isoforms in the intestinal smooth muscle and interstitial cells of Cajal of the Cav1(+/+) and Cav1(-/-) mouse. Histochem. Cell Biol. 2006, 126:9-16.
40. Parton R.G., Simons K. The multiple faces of caveolae. Nat. Rev. Mol. Cell Biol. 2007, 8:185-194.
41. Yagita H., Takeda K., Hayakawa Y., Smyth M.J., Okumura K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci. 2004, 95:777-783.
42. Sheikh M.S., Fornace A.J. Death and decoy receptors and p53-mediated apoptosis. Leukemia 2000, 14:1509-1513.
43. Lawrence D., Shahrokh Z., Marsters S., Achilles K., Shih D., Mounho B., Hillan K., Totpal K., DeForge L., Schow P., Hooley J., Sherwood S., Pai R., Leung S., Khan L., Gliniak B., Bussiere J., Smith C.A., Strom S.S., Kelley S., Fox J.A., Thomas D., Ashkenazi A. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. 2001, 7:383-385.
44. Kelley S.K., Harris L.A., Xie D., Deforge L., Totpal K., Bussiere J., Fox J.A. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp. Ther. 2001, 299:31-38.
45. Shankar S., Chen X., Srivastava R.K. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 2005, 62:165-186.
46. Mayor S., Rao M. Rafts: scale-dependent, active lipid organization at the cell surface. Traffic 2004, 5:231-240.
47. Sharma P., Varma R., Sarasij R.C., Ira, Gousset K., Krishnamoorthy G., Rao M., Mayor S. Nanoscale organization of multiple GPI-anchored proteins in living cell membranes. Cell 2004, 116:577-589.
48. Gajate C., Mollinedo F. The antitumor ether lipid ET-18-OCH(3) induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood 2001, 98:3860-3863.
49. Gajate C., Mollinedo F. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 2007, 109:711-719.
50. Amantana A., London C.A., Iversen P.L., Devi G.R. X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol. Cancer Ther. 2004, 3:699-707.
51. Zhang X., Jin T.G., Yang H., DeWolf W.C., Khosravi-Far R., Olumi A.F. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res. 2004, 64:7086-7091.
52. Li W., Zhang X., Olumi A.F. MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L). Cancer Res. 2007, 67:2247-2255.
53. White S.J., Lu P., Keller G.M., Voelkel-Johnson C. Targeting the short form of cFLIP by RNA interference is sufficient to enhance TRAIL sensitivity in PC3 prostate carcinoma cells. Cancer Biol. Ther. 2006, 5:1618-1623.